So far, the principal treatment of PD is to directly supplement dopamine, such as using the combination of carbidopa and levodopa or dopamine agonists, or to achieve therapeutic maintenance of dopamine by reducing the key metabolism, such as targeting catechol-O-methyltransferase or monoamine oxidase B (MAO-B) using inhibitors2. The gene discussed is MAOB; the disease is Parkinson disease.